PILRB

Across TCGA pan-cancer cohorts, PILRB Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PILRB data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher PILRB Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PILRB expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

BRCA, BLCA, and HNSC are the cancer types where PILRB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.167	0.579	.025	8	view →
BLCA	DFS	Median	III,IV	1.000	0.270	.028	8	view →
HNSC	OS	Median	II,III,IV	0.222	0.710	.031	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	OS	Median	III,IV	0.138	0.841	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PILRB–BRCA (OS)

Open the BRCA breakdown →